134003-83-1

Basic information

• Product Name: (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• Synonyms: (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;tert-butyl (1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• CAS NO: 134003-83-1
• Molecular Formula: C₁₇H₂₄N₂O₂
• Molecular Weight: 288.38466
• Mol File: 134003-83-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 377.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 9.17±0.20(Predicted)
• CAS DataBase Reference: (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate(134003-83-1)
• EPA Substance Registry System: (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate(134003-83-1)

Safety Data

• Hazardous Substances Data: 134003-83-1(Hazardous Substances Data)

Usage

General Description

"(1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate" is a complex organic compound, likely being used in specific scientific and industrial research or processes. It belongs to the class of chemicals known as bicyclic compounds, specifically an example of the diazabicyclo[2.2.1]heptane class, which is known for containing a structure of two fused cyclopropane rings. (1R,4R)-tert-butyl 5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate features a carbamate group (-OC(O)NR2), which is a functional group consisting of a carbonyl group (C=O) linked to an ether group (OR). It also includes a benzyl group (C6H5CH2-), which is often used in organic synthesis due to its stability and resistance to oxidation and reduction. The use and properties of this specific chemical would largely depend on its context and how it's being utilized in particular research or applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 116258-17-4 (1R,4R)-5-phenylmethyl-2,5-diazabicyclo[2.2.1] heptane dihydrobromide 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 61478-26-0 tert-butyl (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylate 
• 61478-27-1 (2S,4S)-N-(tert-butoxycarbonyl)-4-(p-toluenesulfonyloxy)-2-<(p-toluenesulfonyloxy)methyl>pyrrolidine 
• 100-46-9 benzylamine 
• 31560-25-5 5-aza-5-benzoyl-2-oxa-3-oxo-bicyclo<2.2.1>heptane 
• 98-88-4 benzoyl chloride 
• 31560-19-7 (2S,4R)-1-benzoyl-4-hydroxy-L-proline 
• 51-35-4 4R-4-hydroxyproline 
• 120806-96-4 (2S,4S)-1-benzoyl-4-hydroxyproline methyl ester 

Downstream Products

• 134003-84-2 tert-butyl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 
• 286946-75-6 tert-butyl (1R,4R)-5-(5-benzyloxy-3-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 
• 286943-81-5 (1R,4R)-2-(3-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane 

Relevant articles and documents

Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

HDAC INHIBITORS AND USES THEREOF

Inhibitors of histone deacetylase, including compounds having a diazabicyclo[2.2.1]heptan-2-yl moiety are described together with methods for treating various disorders with such compounds.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.